Magnetic Resonance Imaging Study of JM-4 in Multiple Sclerosis/Clinically Patients

Magnetic Resonance Imaging Study of JM-4 in Multiple Sclerosis/Clinically Patients

Publication date: Mar 22, 2019

This is a Phase 0/1 study of MS patients to determine the safety and potential efficacy of a novel, small human peptide designated as JM-4. The study will involve treatment for 5-7 days with JM-4 to determine the effects of Gadolinium(+) lesion number and volume in the brains of patients.

Concepts Keywords
Allergy Magnetic Resonance Imaging
Basal Gadolinium
Brain MRI
Breast Feeding Tumefactive multiple sclerosis
Cerebrovascular Disease Magnetic resonance imaging
CIS Natalizumab
Cohort Neurology
Contraception McDonald criteria
Corticosteroids Autoimmune diseases
Diabetes Mellitus Physical sciences
Diaphragm Neurological disorders
Gadolinium Medical specialties
Gilenya Organ systems
HIV Multiple sclerosis
Hormonal Contraceptive Contraception
Immunosuppressive Drugs Intravenous infusions
Informed Consent Intravenous infusion
Intravenous Multiple Sclerosis MRI
Intravenous Infusion Cohort patients
Kidney
Lesion
Liver
Lung
Magnetic Resonance Imaging
Malignancy
Menopausal
Mitoxantrone
MRI
Multiple Sclerosis
Peptide
Serous
Skin Cancer
Spermicide
Squamous
Systemic Disorder
Tysabri
Uterine

Semantics

Type Source Name
disease MESH infections
disease DOID cerebrovascular disease
disease MESH cerebrovascular disease
disease DOID skin cancer
disease MESH skin cancer
gene UNIPROT EHD1
disease MESH malignancy
drug DRUGBANK Mitoxantrone
drug DRUGBANK Dimethyl fumarate
gene UNIPROT NR4A2
gene UNIPROT ALG3
drug DRUGBANK Methylergometrine
gene UNIPROT SLC35G1
gene UNIPROT GAD1
gene UNIPROT CYREN
gene UNIPROT CISH
drug DRUGBANK Gadolinium
disease DOID Multiple Sclerosis
disease MESH Multiple Sclerosis
disease MESH Sclerosis
disease DOID allergy
disease MESH allergy
disease DOID diabetes mellitus
disease MESH diabetes mellitus

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *